Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?
In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.
MannKind may be on the precipice of growth surge thanks to Afrezza, but these three biotech stocks are still growing faster than MannKind.
The 10 largest hedge funds bought nearly $16 billion worth of stocks in the third quarter, and three of them were their favorites.
Novartis AG and Amgen Inc. have promising new psoriasis drugs that could challenge Johnson & Johnson's Stelara for market share.
The best healthcare stocks in 2014 saw their shares gain as much as 400% because they exhibited at least one of the following three key traits.
These 10 stocks were the top large-cap performers in healthcare during 2014.
There's more to top dividend-paying stocks than the yield.
Achillion Pharmaceuticals is conducting a study that could reduce hepatitis C treatment to six weeks.
Three Motley Fool analysts tell investors which biotechnology stocks are on their wish list this month.